Omeros Corporation (OMER) financial statements (2021 and earlier)

Company profile

Business Address 201 ELLIOTT AVENUE WEST
SEATTLE, WA 98119
State of Incorp. WA
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:1351541654612732
Cash and cash equivalents112127394
Short-term investments1241321447581828
Other undisclosed cash, cash equivalents, and short-term investments (0)000  
Receivables4371624353029
Inventory, net of allowances, customer advances and progress billings1221111
Inventory1221111
Other undisclosed current assets11456754
Total current assets:15119639861046466
Noncurrent Assets
Operating lease, right-of-use asset26262727272117
Property, plant and equipment10333444
Prepaid expense1111111
Restricted cash and investments1111111
Other undisclosed noncurrent assets(8)      
Total noncurrent assets:30313233332724
TOTAL ASSETS:181227711181379190
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities33443454524438
Accounts payable479135106
Accrued liabilities29372641473432
Debt1444433
Other undisclosed current liabilities3      
Total current liabilities:37483858554741
Noncurrent Liabilities
Long-term debt and lease obligation236263194192191184179
Long-term debt, excluding current maturities236233163161158156153
Finance lease, liability 111212
Operating lease, liability 292930312724
Liabilities, other than long-term debt 4     
Deferred income tax liabilities 4     
Total noncurrent liabilities:236267194192191184179
Total liabilities:273314232250246231220
Stockholders' equity
Stockholders' equity attributable to parent(121)(87)(161)(132)(109)(140)(130)
Common stock1111100
Additional paid in capital751747635631625565558
Accumulated deficit(873)(835)(797)(764)(735)(705)(689)
Total stockholders' equity:(121)(87)(161)(132)(109)(140)(130)
Other undisclosed liabilities and equity29      
TOTAL LIABILITIES AND EQUITY:181227711181379190

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues11261424333027
Cost of revenue
(Cost of Goods and Services Sold)
(0)(0)(0)(0)(0)(0)(0)
Gross profit:11261323333027
Operating expenses(44)(51)(41)(47)(57)(41)(36)
Operating loss:(34)(25)(28)(24)(24)(11)(9)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
0(1)01000
Interest and debt expense(8)(20)(6)(6)(6)(6)(6)
Loss from continuing operations before income taxes:(41)(46)(33)(29)(29)(16)(14)
Income tax benefit48     
Net loss available to common stockholders, diluted:(37)(38)(33)(29)(29)(16)(14)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(37)(38)(33)(29)(29)(16)(14)
Comprehensive loss, net of tax, attributable to parent:(37)(38)(33)(29)(29)(16)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: